stillwork
Peptide

Tirzepatide

Dual incretin powerhouse

A dual GIP/GLP-1 receptor agonist offering superior metabolic benefits. Combines two incretin pathways for enhanced weight loss and glucose control.

Mechanisms

  • Dual GIP/GLP-1 agonism
  • Enhanced satiety
  • Improved insulin sensitivity
  • Greater weight loss

Dosing

Typical dose

2.5–15mg

Timing

Weekly injection with gradual titration. Superior weight loss vs single agonists.

Synergies

Semaglutide

Semaglutide and Tirzepatide both support metabolic health (not typically combined)

Mild

Interactions

Retatrutide

Tirzepatide and Retatrutide both target GLP-1 - choose one

Avoid
Semaglutide

Semaglutide and Tirzepatide should not be combined - overlapping GLP-1 mechanisms

Avoid

Research

RCT2022

Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1)

Jastreboff AM et al·NEJM

Tirzepatide produced 20.9% weight loss at highest dose vs 3.1% placebo at 72 weeks